Discussion {#onco12195-sec-0001}
==========

Ofatumumab, obinutuzumab, and rituximab are all effective anti‐CD20 monoclonal antibodies that can cause side effects during or after infusion. However, previous studies using rituximab show that infusion‐related reactions can be overcome by first starting with a lower dose and then giving a second larger dose within a few days of the initial dose. Such an approach allows for the rapid infusion of rituximab in subsequent doses in patients with CLL. Our completed phase II study of ofatumumab in patients with CLL clearly corroborates the feasibility of reducing the frequency of infusion‐related reactions by using this same approach. As shown in Table [1](#onco12195-tbl-0001){ref-type="table"} and Table [2](#onco12195-tbl-0002){ref-type="table"}, the number of patients with CLL that experienced infusion‐related reactions steadily decreased at each infusion (infusion 1: 62%; infusion 2: 12%, and infusion 3: 3%). These results underscore that our study design was successful and appropriate for the 97% of patients with CLL who completed infusion 3 and, of those, the 87% who completed infusion 3 within the 2‐hour treatment plan.

###### Summary of ofatumumab infusion times

![](onco12195-tbl-0001){#nlm-graphic-1}

###### Infusion‐related toxicities

![](onco12195-tbl-0002){#nlm-graphic-3}

Abbreviation: ---, no occurrence.

A stepped‐up dosing schedule of ofatumumab has implications that go beyond minimizing infusion‐related reactions and avoiding wasted medication; it also addresses quality‐of‐life concerns. The less time that patients spend in the oncologist\'s office equates to more time that patients can spend doing more pleasurable activities.

Trial Information {#onco12195-sec-1111}
=================

**Disease**Leukemia -- chronic -- CLL**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**One prior regimen**Type of Study ‐ 1**Phase II**Type of Study ‐ 2**Single arm**Primary Endpoint**Deliverability**Secondary Endpoint**Safety**Secondary Endpoint**Objective response rate**Secondary Endpoint**Toxicity**Secondary Endpoint**Progression‐free survival**Additional Details of Endpoints or Study Design** The primary endpoint was to determine the proportion of patients able to complete rapid infusion 3 within 15 minutes of the planned 2‐hour treatment. Ofatumumab has been associated with infusion reactions, which have led to temporary interruption of treatment or withdrawal of treatment. To attenuate infusion‐related reactions in our study, patients were premedicated 30 minutes to 2 hours prior to infusion with acetaminophen 1,000 mg p.o., diphenhydramine 50 mg p.o./IV or equivalent, and dexamethasone 10 mg IV. Dose reductions of ofatumumab were not allowed. For grade 1 or 2 infusion reactions, the infusion was temporarily interrupted. Once the patient was stable, the infusion was restarted at half of the infusion rate at the time the infusion was paused. Thereafter, the rate could be increased at the discretion of the investigator. For grade 3 infusion reactions, the infusion was interrupted and the appropriate clinical intervention was implemented. When the event decreased to grade \<3, the infusion was restarted at half of the infusion rate at the time the infusion was stopped. Thereafter, the rate could be increased at the discretion of the investigator. If the grade 3 infusion reaction did not resolve or a grade 4 reaction occurred, the patient was permanently discontinued from the study treatment. Of the 21 patients who experienced an infusion reaction during the infusion, 10 patients (48%) had their infusion interrupted (stopped and restarted), 8 patients (38%) had the rate of infusion reduced, 4 patients (19%) stopped the infusion, and 2 patients (10%) had no modification to the infusion in the presence of an infusion‐related reaction. **Investigator\'s Analysis**Active and should be pursued further

Drug Information for Phase II Ofatumumab {#onco12195-sec-2111}
========================================

**Drug 1** **Generic/Working name**Ofatumumab**Trade name**Arzerra**Company name**Novartis and GlaxoSmithKline**Drug type**Antibody**Drug class**CD20**Dose**Infusion 1: 300 mg; infusion 2: 1,000 mg; infusion 3: 2,000 mg milligrams (mg) per flat dose**Route**IV**Schedule of administration** Day 1: 300 mg, starting at 3.6 mg/hour and doubling every 30 minutes until a rate of 240 mg/hour was reached. Day 3: 1,000 mg, starting at 50 mg/hour and doubling every 30 minutes until a rate of 800 mg/hour was reached. Day 8: 2,000 mg; if tolerated, the third dose was given on week 2 day 1 at 800 mg/hour over the first 30 minutes and, if tolerated, at 1,068 mg/hour over the next 90 minutes (goal infusion time 120 minutes). Premedication regimen (30 minutes to 2 hours before treatment): acetaminophen 1,000 mg p.o.; diphenhydramine 50 mg p.o./IV or equivalent; dexamethasone 10 mg IV. 28‐day cycle with ofatumumab. 

Patient Characteristics for Phase II Ofatumumab {#onco12195-sec-3111}
===============================================

**Number of patients, male**17**Number of patients, female**17**Stage**Rai stage 0: 3 (9%)Rai stage 1: 8 (23%)Rai stage 2: 7 (21%)Rai stage 3: 4 (12%)Rai stage 4: 11 (32%)Unknown: 1 (3%)**Age**Median (range): 70 (53--89)**Number of prior systemic therapies**Median (range): 1 (1--5)**IgVH mutation status** Mutated9 (26%)Non‐mutated18 (53%)Not done7 (21%)**CD38** Positive13 (38%)Negative18 (53%)Not done3 (9%)**ZAP‐70** Positive18 (53%)Negative5 (15%)Unknown11 (32%)**FISH** Normal8 (24%)Abnormal25 (73%)11q del8 (24%)13q del15 (44%)17p del6 (18%)Trisomy 128 (24%)Unknown/Not done1 (3%)**Cancer Types or Histologic Subtypes**Chronic lymphocytic leukemia: 34Chronic lymphocytic leukemia, poor risk: 13

Primary Assessment Method for Phase II Ofatumumab {#onco12195-sec-4111}
=================================================

Assessment Number of patients enrolled13Number of patients evaluable for toxicity12Number of patients evaluated for efficacy12Evaluation methodInternational Workshop on CLL Working Group (IWCLL WG) diagnostic criteriaResponse assessment CR*n* = 0 (0%)Response assessment PR*n* = 0 (0%)Response assessment SD*n* = 11 (92%)Response assessment PD*n* = 1 (8%)Response assessment OTHER*n* = 1 (8%)Assessment Number of patients screened34Number of patients enrolled34Number of patients evaluable for toxicity31Number of patients evaluated for efficacy31Evaluation methodIWCLL WG diagnostic criteriaResponse assessment CR*n* = 0 (0%)Response assessment PR*n* = 6 (32%)Response assessment SD*n* = 11 (58%)Response assessment PD*n* = 2 (10%)Response assessment OTHER*n* = 2 (10%)(Median) duration assessments PFS9.2485 months, CI: 95%(Median) duration assessments OS0 months, CI: 95%

Response Assessment Table {#onco12195-sec-5111}
=========================

**Response assessmentAll patients, *n* = 31, *n* (%)**ORR6 (19%)PR6 (19%)SD22 (71%)PD3 (10%)Unevaluable^a^3 (10%)^a^Three patients discontinued treatment prior to assessment. Abbreviations: ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease. 

Adverse Events: Phase II Ofatumumab {#onco12195-sec-7111}
===================================

imageJohn Wiley & Sons, Ltd.[^1][^2][^3]

Serious Adverse Events {#onco12195-sec-8111}
======================

imageJohn Wiley & Sons, Ltd.[^4][^5][^6]

Assessment, Analysis, and Discussion {#onco12195-sec-6111}
====================================

CompletionStudy completedInvestigator\'s AssessmentActive and should be pursued further

 {#onco12195-sec-0002}

The anti‐CD20 antibodies, either alone or in combination, have become an integral part of the treatment of patients with B‐cell lymphomas and chronic lymphocytic leukemia (CLL). However, infusions of the antibodies can be difficult in patients with CLL due to an increase in infusion reactions such as fever and hypotension. The observation with rituximab that these reactions are generally worse on the first infusion than on subsequent doses has led to the development of alternative dosing regimens in CLL.

Ofatumumab (OFA) is a fully human anti‐CD20 antibody that induces B‐cell lysis primarily through complement‐dependent cytotoxicity (CDC) and antibody‐dependent cell‐mediated cytotoxicity \[[1](#onco12195-bib-0001){ref-type="ref"}\]. It recognizes a different epitope of the CD20 molecule than rituximab \[[2](#onco12195-bib-0002){ref-type="ref"}\], \[[3](#onco12195-bib-0003){ref-type="ref"}\]. Ofatumumab was found to be effective in the pivotal GSK 406 study of 223 patients with CLL \[[4](#onco12195-bib-0004){ref-type="ref"}\]. Interestingly, ≥90% of patients in the GSK 406 study did not have significant infusion‐related reactions following the second OFA dose. Furthermore, the majority of the reported infusion‐related reactions were Grade 1 or 2 and the median duration of the third dose was 4.3 hours (range 2.6--21.3). The GSK 406 data suggest that the infusion rate of OFA could be accelerated, which aligns with other trials using the anti‐CD20 antibody, rituximab \[[5](#onco12195-bib-0005){ref-type="ref"}\], \[[6](#onco12195-bib-0006){ref-type="ref"}\], \[[7](#onco12195-bib-0007){ref-type="ref"}\].

While previous and ongoing studies report that OFA is safe, well tolerated, and has demonstrated significant activity in patients with CLL \[[4](#onco12195-bib-0004){ref-type="ref"}\], \[[5](#onco12195-bib-0005){ref-type="ref"}\], \[[6](#onco12195-bib-0006){ref-type="ref"}\], \[[7](#onco12195-bib-0007){ref-type="ref"}\], the issue for many patients and physicians is the 4‐hour infusion time. The purpose of this study was to evaluate an accelerated infusion regimen that allows the third OFA 2,000 mg infusion to be safely delivered over a 2‐hour time period to patients with CLL. We found that 87% of patients could complete the third dose (2,000 mg) within 2 hours, which was the primary endpoint of the study. It is important to note that the second dose of OFA was given 2 days after the first dose rather than the standard approach of giving it a week later. This schedule was chosen based on our previous experience of giving rituximab thrice weekly and the hypothesis that giving anti‐CD20 antibodies in close sequence increases tolerability by preventing rebound after the initial infusion \[[5](#onco12195-bib-0005){ref-type="ref"}\].

Figures and Tables {#onco12195-sec-1105}
==================

![Progression‐free survival.](onco12195-fig-0001){#onco12195-fig-0001}

![Overall survival.](onco12195-fig-0002){#onco12195-fig-0002}

###### Patient characteristics
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Abbreviations: ALC, absolute lymphocytic count; OFA, ofatumumab.
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[^1]: Adverse events account for all 34 patients.

[^2]: Infusion‐related reactions: one patient, grade 3 dyspnea (infusion 1 and infusion 2)/facial flushing (infusion 1); one patient, grade 3 hives (infusion 1).

[^3]: Abbreviation: NC/NA, no change from baseline/no adverse event.

[^4]: Number of treatment related deaths: 0; number of related SAEs: 4.

[^5]: Total number of patients with related SAEs: 3 (grade 3 SAEs, 1 patient each).

[^6]: Abbreviation: SAE, serious adverse event.
